Literature DB >> 18440262

Analysis of mRNA transcripts improves the success rate of molecular genetic testing in OTC deficiency.

Katharina Engel1, Jean-Marc Nuoffer, Chris Mühlhausen, Vera Klaus, Carlo R Largiadèr, Konstantinos Tsiakas, René Santer, Bendicht Wermuth, Johannes Häberle.   

Abstract

BACKGROUND: Ornithine transcarbamylase (OTC) deficiency is the most common inborn error of urea metabolism that can lead to hyperammonemic crises and orotic aciduria. To date, a total of 341 causative mutations within the OTC gene have been described. However, in about 20% of the patients with enzymatically confirmed OTC deficiency no mutation can be detected when sequencing of genomic DNA analyzing exons and adjacent intronic segments of the OTC gene is performed.
METHODS: Standard genomic DNA analysis of the OTC gene in five consecutive patients from five families revealed no mutation. Hence, liver tissue was obtained by needle sampling or open biopsy and RNA extracted from liver was analyzed.
RESULTS: Complex rearrangements of the OTC transcript (three insertions and two deletions) were found in all five patients.
CONCLUSION: In patients with a strong suspicion of OTC deficiency despite normal results of sequencing exonic regions of the OTC gene, characterization of liver OTC mRNA is highly effective in resolving the genotype. Liver tissue sampling by needle aspiration allows for both enzymatic analysis and RNA based diagnostics of OTC deficiency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440262     DOI: 10.1016/j.ymgme.2008.03.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  12 in total

1.  Determination of mutation patterns in human ornithine transcarbamylase precursor.

Authors:  Shaomin Yan; Guang Wu
Journal:  J Clin Monit Comput       Date:  2009-02-10       Impact factor: 2.502

Review 2.  Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery.

Authors:  Belen Pérez; Lluisa Vilageliu; Daniel Grinberg; Lourdes R Desviat
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

3.  Disease-causing mutations in the promoter and enhancer of the ornithine transcarbamylase gene.

Authors:  Yoon J Jang; Abigail L LaBella; Timothy P Feeney; Nancy Braverman; Mendel Tuchman; Hiroki Morizono; Nicholas Ah Mew; Ljubica Caldovic
Journal:  Hum Mutat       Date:  2018-01-16       Impact factor: 4.878

Review 4.  [Consensus on diagnosis and treatment of ornithine trans-carbamylase deficiency].

Authors: 
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-25

Review 5.  Suggested guidelines for the diagnosis and management of urea cycle disorders.

Authors:  Johannes Häberle; Nathalie Boddaert; Alberto Burlina; Anupam Chakrapani; Marjorie Dixon; Martina Huemer; Daniela Karall; Diego Martinelli; Pablo Sanjurjo Crespo; René Santer; Aude Servais; Vassili Valayannopoulos; Martin Lindner; Vicente Rubio; Carlo Dionisi-Vici
Journal:  Orphanet J Rare Dis       Date:  2012-05-29       Impact factor: 4.123

6.  Functional characterization of the spf/ash splicing variation in OTC deficiency of mice and man.

Authors:  Ana Rivera-Barahona; Rocío Sánchez-Alcudia; Hiu Man Viecelli; Veronique Rüfenacht; Belén Pérez; Magdalena Ugarte; Johannes Häberle; Beat Thöny; Lourdes Ruiz Desviat
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

Review 7.  Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature.

Authors:  Catia Cavicchi; Chiara Chilleri; Antonella Fioravanti; Lorenzo Ferri; Francesco Ripandelli; Cinzia Costa; Paolo Calabresi; Paolo Prontera; Francesca Pochiero; Elisabetta Pasquini; Silvia Funghini; Giancarlo la Marca; Maria Alice Donati; Amelia Morrone
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

8.  A deep intronic variant is a common cause of OTC deficiency in individuals with previously negative genetic testing.

Authors:  Runjun D Kumar; Lindsay C Burrage; Jan Bartos; Saima Ali; Eric Schmitt; Sandesh C S Nagamani; Cynthia LeMons
Journal:  Mol Genet Metab Rep       Date:  2021-01-08

9.  A sensitive assay system to test antisense oligonucleotides for splice suppression therapy in the mouse liver.

Authors:  Lorena Gallego-Villar; Hiu Man Viecelli; Belén Pérez; Cary O Harding; Magdalena Ugarte; Beat Thöny; Lourdes R Desviat
Journal:  Mol Ther Nucleic Acids       Date:  2014-09-16       Impact factor: 10.183

10.  Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test.

Authors:  Anath C Lionel; Gregory Costain; Nasim Monfared; Susan Walker; Miriam S Reuter; S Mohsen Hosseini; Bhooma Thiruvahindrapuram; Daniele Merico; Rebekah Jobling; Thomas Nalpathamkalam; Giovanna Pellecchia; Wilson W L Sung; Zhuozhi Wang; Peter Bikangaga; Cyrus Boelman; Melissa T Carter; Dawn Cordeiro; Cheryl Cytrynbaum; Sharon D Dell; Priya Dhir; James J Dowling; Elise Heon; Stacy Hewson; Linda Hiraki; Michal Inbar-Feigenberg; Regan Klatt; Jonathan Kronick; Ronald M Laxer; Christoph Licht; Heather MacDonald; Saadet Mercimek-Andrews; Roberto Mendoza-Londono; Tino Piscione; Rayfel Schneider; Andreas Schulze; Earl Silverman; Komudi Siriwardena; O Carter Snead; Neal Sondheimer; Joanne Sutherland; Ajoy Vincent; Jonathan D Wasserman; Rosanna Weksberg; Cheryl Shuman; Chris Carew; Michael J Szego; Robin Z Hayeems; Raveen Basran; Dimitri J Stavropoulos; Peter N Ray; Sarah Bowdin; M Stephen Meyn; Ronald D Cohn; Stephen W Scherer; Christian R Marshall
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.